Status:

TERMINATED

Development of A Novel Anti-Hyperglycemic Agent

Lead Sponsor:

VA Office of Research and Development

Conditions:

Diabetes

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this clinical trial is to test the effectiveness and safety of a new anti-diabetes drug (Cyclo-Z) for the prevention and treatment of Type 2 diabetes. This study will determine dose-dep...

Detailed Description

We have demonstrated that a cyclic dipeptide Cyclo (his-pro) plus zinc (Cyclo-Z) treatment improved clinical conditions of diabetes in various animal models and a phase 1 clinical trial. The main obje...

Eligibility Criteria

Inclusion

  • History of type 2 diabetes mellitus who are na ve to hypoglycemic treatment, inadequately controlled by diet and exercise alone or oral medications.
  • Hemoglobin A1c level of 6.5 % to 8.0 % inclusive. Subjects not taking hypoglycemic drugs with HgbA1c of 6.0% to 6.5% must have a diagnosis of Diabetes Mellitus (DM).
  • Fasting blood glucose levels reasonably stable for at least 2 months or during the two-week lead-in-period.
  • Ethnicity: All ethnic groups.
  • Gender: Both men and women.
  • Female with reproductive potential must not be pregnant or lactating, and using reliable contraception methods.
  • Age \>18 years old.

Exclusion

  • Taking insulin.
  • History of diabetic ketoacidosis or hyper osmolar non-ketotic coma.
  • Diabetes Mellitus related end-organ damage:
  • Evidence of diabetic autonomic and peripheral neuropathy
  • Diabetic proliferative retinopathy, based on eye exam by ophthalmologist
  • Diabetes nephropathy defined by \> 500 mg/24 hour urinary albumin excretion
  • Any disease likely to limit life span and/or increase risks of interventions:
  • Screening carotid B-mode ultrasound indicating clinically significant stenos in the common carotid arteries requiring intervention by angioplasty or resection.
  • Cancer treatment in the past 5 years, with the exception of cancers that have been cured, and carry a good prognosis.
  • Infectious disease: HIV positivity, active tuberculosis, or pneumonia.
  • Cardiovascular disease:
  • Hospitalization for treatment of heart disease in the past 12 months.
  • New York Heart Association Functional Class \> 2.
  • Left Bundle branch block on EKG.
  • Third degree atrioventricular block on EKG.
  • Uncontrolled hypertension with average systolic blood pressure of \> 160 mmHg on two screening visits and diastolic blood pressure \> 95 mmHg on two screening visit.
  • Pulse rate \> 95 beats per minute on both screening visits.
  • Stroke or transient ischemic attack in the past 12 months.
  • Gastrointestinal disease:
  • Chronic hepatitis or cirrhosis.
  • Episode of alcoholic hepatitis or alcoholic pancreatitis.
  • Inflammatory bowel disease requiring treatment in the past 12 months.
  • Recent or significant abdominal surgery (e.g. gastrectomy, gastric bypass).
  • Renal disease: Serum creatinine \> 1.5 mg/dL for men, and \> 1.4 mg/dL for women.
  • Lung disease:
  • Chronic obstructive airway disease or asthma requiring daily therapy.
  • Use of home oxygen.
  • Anemia: Hematocrit of \< 36.0% in men or \< 33% in women.
  • Conditions or behaviors likely to affect the conduct of the study
  • Unable or unwilling to give informed consent.
  • Unable to communicate with the clinic staff.
  • Unwilling to accept treatment assignment by randomization.
  • Weight loss of \> 10% in the past 6 months.
  • Unable to walk without any assisted device.
  • Major psychiatric disorder which would impede conduct of the research.
  • Excessive alcohol intake (more than 2 drinks/day)
  • Medications
  • Psychoactive agents such as Monoamine oxidase inhibitors and Antidepressive agents (lithium, prozac, zoloft, serzone, paxil, effexor)
  • Systemic use of glucocorticoids steroids within previous 6 weeks.

Key Trial Info

Start Date :

April 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2013

Estimated Enrollment :

38 Patients enrolled

Trial Details

Trial ID

NCT00878605

Start Date

April 1 2010

End Date

September 30 2013

Last Update

June 14 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

West Los Angeles, California, United States, 90073